TP53 and small cell lung carcinoma: We next aimed to better characterize the differences in the genomic and clinicopathologic characteristics of aSCLC versus the de novo SCLC in never-smokers harboring RB1 and TP53 genomic mutations (nsSCLC-RB1−/TP53−; n = 18).